Irisin in metabolic diseasesStergios A. Pοlyzos, Christos S. Mantzoros, Athanasios D. Anastasilakis et al.|Endocrine|2017Cited by 258
Irisin in patients with nonalcoholic fatty liver diseaseStergios A. Pοlyzos, Christos S. Mantzoros, Јannis Kountouras et al.|Metabolism|2013Cited by 216
Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body CompositionAthanasios D. Anastasilakis, Christos S. Mantzoros, Zacharias G. Saridakis et al.|The Journal of Clinical Endocrinology & Metabolism|2014Cited by 189
Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept studyNikolaos Perakakis, Christos S. Mantzoros, Stergios A. Pοlyzos et al.|Metabolism|2019Cited by 135
Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 monthsAthanasios D. Anastasilakis, Christos S. Mantzoros, Athina Gkiomisi et al.|Osteoporosis International|2014Cited by 133